Premium
Minocycline in neurodegenerative and psychiatric diseases: An update
Author(s) -
RomeroMiguel Diego,
LamannaRama Nicolás,
CasqueroVeiga Marta,
GómezRangel Vanessa,
Desco Manuel,
SotoMontenegro María Luisa
Publication year - 2021
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/ene.14642
Subject(s) - minocycline , medicine , clinical trial , disease , antibiotics , psychiatry , bioinformatics , microbiology and biotechnology , biology
Minocycline is a broad-spectrum antibiotic, effective as a chronic treatment for recurrent bacterial infections. Beyond its antibiotic action, minocycline also has important anti-inflammatory, antioxidant and antiapoptotic properties. Its efficacy has therefore been evaluated in many neurodegenerative and psychiatric diseases that have an inflammatory basis. Our aim was to review preclinical and clinical studies performed in neurological and psychiatric diseases whose treatment involved the use of minocycline and thereby to discern the possible beneficial effect of minocycline in these disorders.